Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles PivotalPath: The Dramatic Market Rebound in April Tested Quant Funds — But They Eked Out Gains Julie Segal Allocator Rising Stars Are Carving Out Their Own Paths in an Uncertain Moment James Comtois How Nonprofits of Varying Sizes Can Tap Into Big-firm Investment Expertise Sponsored by Fidelity Investments